Breast Neoplasms
Conditions
Keywords
metastatic breast cancer, locally advanced, unresectable breast cancer, HER2/NEU negative
Brief summary
This is a pilot phase 1b study to investigate the safety and side effects of combining the ROR1-targeting monoclonal antibody, cirmtuzumab, with paclitaxel for patients with HER2 negative, metastatic breast cancer. Cirmtuzumab is a type of drug called a monoclonal antibody. This drug is designed to attach to a protein called receptor-tyrosine-kinase like orphan receptor 1 (ROR1) on the surface of breast cancer cells. Cirmtuzumab blocks the growth and survival of the breast cancer cells in laboratory tests. ROR1 is rarely expressed on healthy cells. Cirmtuzumab is considered experimental and is not approved by United States (U.S.) Food and Drug Administration (FDA).
Detailed description
* This is a phase 1b, open-label, non-randomized, fixed dose study in patients with HER2 negative metastatic, or locally advanced, unresectable breast cancer. * Cirmtuzumab and paclitaxel will be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity, as long as the subject is tolerating the drug and does not exhibit disease progression. * Blood and tissue samples will be collected at pre-specified times to enable pharmacokinetic and correlative studies. * Adverse events (AE) will be monitored throughout the trial. Reporting of AEs will be in accordance with CTCAE version 4.03. * Assessment of tumor response will be performed by physical examination and/or by radiographic imaging and according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1. * Patients will be assessed at 28 days following the last dose of cirmtuzumab to assess tumor response and at 56 days following the last dose of cirmtuzumab to assess any adverse events and to document any concomitant cancer therapy.
Interventions
DRUGCirmtuzumab + Paclitaxel
Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
Sponsors
Oncternal Therapeutics, Inc
Barbara Parker, MD
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy-confirmed, metastatic or locally advanced surgically unresectable, HER2 negative breast cancer. HER2 status should reflect the most recent biopsy results. Note: HER2 negative breast cancer is defined according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines 2013 for HER2 testing performed in a CLIA-certified laboratory. * ER/PR negative (\<10% of cells staining for ER or PR) breast cancer or have ER/PR positive (≥10% of cells staining for ER or PR) breast cancer that has exhausted standard endocrine therapy and/or in the opinion of the treating oncologist, warrants cytotoxic chemotherapy. * Measurable disease as defined by RECIST v1.1. Measurable lesions will be confirmed by radiographic imaging (CT or MRI). Patients with bone only disease will be eligible if disease is considered measurable and a soft tissue component is present and can be biopsied.. * There is no limit to prior lines of therapy, but patients must not have received prior taxane chemotherapy in the metastatic setting. * ECOG Performance Status ≤ 2. * Adequate organ function as defined below: * Absolute Neutrophil Count ≥ 1.0 x 10\^9/L * Platelet count ≥ 100,000 /μL * Hemoglobin ≥ 8.0 g/dL * Total bilirubin ≤ 1.5 x upper limit of normal * AST and ALT ≤ 3 x upper limit of normal * Serum creatinine ≤ 2 x upper limit of normal OR Creatinine clearance \> 40 ml/min/1.73 m\^2 * Women of child-bearing potential and male subjects who are sexually active with a woman of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for at least 6 months following last infusion of cirmtuzumab. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Existing neuropathy must be no greater than Grade 1. * No concurrent antibody therapy can be planned with the exception of denosumab for use in bone metastasis. * CNS metastases are allowed as long as the metastases are asymptomatic, have been treated with radiation, and have been stable for \> 6 weeks off steroids.
Exclusion criteria
* Patient is currently receiving chemotherapy or has received another chemotherapy within 5 half-lives, radiotherapy or immunotherapy within 2 weeks prior to study treatment initiation. * Patient has known, untreated and/or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis. * Patient had disease that was refractory to paclitaxel in the neoadjuvant setting and/or developed metastatic breast cancer within 6 months of neoadjuvant or adjuvant taxane chemotherapy. * Patient has had major surgery within 3 weeks prior to enrollment. * Patient has severe and/or uncontrolled medical disease(s) (i.e., myocardial infarction within 6 months of study, CKD stage IV or above, severe chronic pulmonary disease or active infection). * The patient has known acute or chronic hepatitis B or C. * The patient has a history of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel. * The patient has a history of another malignancy within 2 years prior to study entry, except curatively treated non-melanotic skin cancer, cervical carcinoma in situ or stage I colon cancer. * Patient has a history of non-compliance or other medical illness that would preclude compliance with study procedures. * Patient has a known diagnosis of human immunodeficiency virus (HIV) infection. * Patient has severe cardiac insufficiency (NYHA III or IV) with uncontrolled and/or unstable cardiac or coronary artery disease * Patient is pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting Toxicities During the First 4 Weeks of Treatment | Within 4 weeks of starting study treatment | Clinically significant adverse events per CTCAE Version 4.03 at least possibly related to cirmtuzumab or the combination of cirmtuzumab and paclitaxel during the first four weeks of investigational treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events | 55 weeks | Treatment-emergent adverse events beginning from the start of study treatment to 30 days after study treatment completion or start of new anti-cancer therapy. |
| Objective Tumor Response Rate | 55 weeks | Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. |
| Best Tumor Response Rate | 12 months | The proportion of patients that achieve a response of stable disease or better as assessed by RECIST v1.1 |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cirmtuzumab + Paclitaxel Cirmtuzumab 600 mg is administered intravenously on Days 1 and 15 of the first 28-day cycle, then on Day 1 of each subsequent 28-day cycle.
Paclitaxel 80 mg/m\^2 is administered weekly on Days 1, 8, 15, and 22 of each 28-day cycle.
Cirmtuzumab + Paclitaxel: Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity. | 16 |
| Total | 16 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Screen failures. One subject ended treatment early due to disease related symptoms | 7 |
Baseline characteristics
| Characteristic | Cirmtuzumab + Paclitaxel |
|---|---|
| Age, Continuous | 52.56 years STANDARD_DEVIATION 11.34 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 12 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 11 Participants |
| Sex: Female, Male Female | 16 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 16 |
| other Total, other adverse events | 16 / 16 |
| serious Total, serious adverse events | 5 / 16 |
Outcome results
Primary
Dose-limiting Toxicities During the First 4 Weeks of Treatment
Clinically significant adverse events per CTCAE Version 4.03 at least possibly related to cirmtuzumab or the combination of cirmtuzumab and paclitaxel during the first four weeks of investigational treatment.
Time frame: Within 4 weeks of starting study treatment
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cirmtuzumab + Paclitaxel | Dose-limiting Toxicities During the First 4 Weeks of Treatment | 0 participants |
Secondary
Best Tumor Response Rate
The proportion of patients that achieve a response of stable disease or better as assessed by RECIST v1.1
Time frame: 12 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cirmtuzumab + Paclitaxel | Best Tumor Response Rate | 12 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events
Treatment-emergent adverse events beginning from the start of study treatment to 30 days after study treatment completion or start of new anti-cancer therapy.
Time frame: 55 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cirmtuzumab + Paclitaxel | Number of Participants With Treatment-emergent Adverse Events | 16 participants |
Secondary
Objective Tumor Response Rate
Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.
Time frame: 55 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cirmtuzumab + Paclitaxel | Objective Tumor Response Rate | 6 Participants |